WO2021147937A1 - 抗st2抗体及其应用 - Google Patents
抗st2抗体及其应用 Download PDFInfo
- Publication number
- WO2021147937A1 WO2021147937A1 PCT/CN2021/073009 CN2021073009W WO2021147937A1 WO 2021147937 A1 WO2021147937 A1 WO 2021147937A1 CN 2021073009 W CN2021073009 W CN 2021073009W WO 2021147937 A1 WO2021147937 A1 WO 2021147937A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- variable region
- chain variable
- region shown
- light chain
- Prior art date
Links
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims abstract description 74
- 239000012634 fragment Substances 0.000 claims abstract description 55
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 claims abstract description 50
- 108010067003 Interleukin-33 Proteins 0.000 claims abstract description 50
- 102000017761 Interleukin-33 Human genes 0.000 claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 102000055002 human IL1RL1 Human genes 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 13
- 230000037361 pathway Effects 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 27
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
- 230000008482 dysregulation Effects 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000000592 Nasal Polyps Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 claims description 5
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 4
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 108010002616 Interleukin-5 Proteins 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 4
- 230000022023 interleukin-5 production Effects 0.000 abstract description 2
- 230000031146 intracellular signal transduction Effects 0.000 abstract description 2
- 230000017306 interleukin-6 production Effects 0.000 abstract 1
- 230000021995 interleukin-8 production Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 46
- 230000000694 effects Effects 0.000 description 41
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 238000012216 screening Methods 0.000 description 24
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 18
- 230000027455 binding Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 241001529936 Murinae Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000012224 working solution Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000004091 panning Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 4
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 3
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- -1 IMGT Chemical compound 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102100033500 Interleukin-33 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229950003468 dupilumab Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000045906 human IL33 Human genes 0.000 description 2
- 229940124622 immune-modulator drug Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960005108 mepolizumab Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229950008998 tezepelumab Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102220512038 AP-4 complex subunit sigma-1_C259S_mutation Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102220348525 c.623G>C Human genes 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000055228 human IL5 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000002352 nuocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000003030 reporter gene method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- Interleukin 33 is a cytokine related to IL-1 and IL-18, also known as NF-HEV or IL-1F11.
- ST2 (ST2L, IL-1RL1, T1, Fit-1, DER-4, IL-1R4, or ST2 ⁇ ) is a binding receptor for IL-33. It is a member of the Toll/IL-1 receptor family.
- IL-33 has been described as an "alarm factor" because it is present in the nucleus of epithelial cells and endothelial cells in a full-length form during homeostasis, but it can be lysed and released during cell necrosis.
- Examples of cellular responses induced by IL-33 include the production of inflammatory cytokines such as IL-5, IL-6, IL-13, TNF, IFN- ⁇ and GM-CSF, and chemotaxis such as CXCL8, CCL17 and CCL24 Factor generation.
- IL-33 has also been shown to enhance acute allergic reactions by enhancing the activation of mast cells and basophils triggered by IgE receptor signal transduction or other mast cell and basophil activators.
- IL-33 can also enhance the recruitment, survival and adhesion properties of immune cells expressing ST2, and therefore has important significance in stimulating and maintaining cellular inflammation in local tissues.
- Inhibitors against this pathway mainly include: IL33 antibody (such as: MEDI3506, ANB020, REGN3500, MT-2990, LY-3375880, PF-06817024) and ST2 antibody (such as: CNTO7160, AMG-282), these antibodies under investigation are all It is in clinical phase 1 and phase 2, and its indications include allergic rhinitis, atopic dermatitis, chronic obstructive pulmonary disease, asthma, etc.
- IL33 antibody such as: MEDI3506, ANB020, REGN3500, MT-2990, LY-3375880, PF-06817024
- ST2 antibody such as: CNTO7160, AMG-282
- the technical problem to be solved by the present invention is to immunize mice with human ST2 as an immunogen, obtain mouse antibodies through B cell panning, and further obtain new high-affinity antibodies that bind to ST through antibody engineering and humanization technology, and The antibody is suitable for the treatment of diseases or any indications related to the IL-33/ST2 pathway.
- the purpose of the present invention is to provide an antibody or functional fragment thereof that specifically binds to ST2, and to provide its use.
- fragment of the antibody of the present invention encompasses various functional fragments or active fragments of the antibody, for example, its antigen-binding portion, such as Fab, F(ab')2 or scFv fragments.
- (I-2) The heavy chain variable region shown in SEQ ID NO. 2 and the light chain variable region shown in SEQ ID NO. 30;
- (II-1) The heavy chain variable region shown in SEQ ID NO. 4 and the light chain variable region shown in SEQ ID NO. 32;
- VI-2 The heavy chain variable region shown in SEQ ID NO.21 and the light chain variable region shown in SEQ ID NO.47;
- VI-6 The heavy chain variable region shown in SEQ ID NO.23 and the light chain variable region shown in SEQ ID NO.47;
- VII-1) The heavy chain variable region shown in SEQ ID NO. 25 and the light chain variable region shown in SEQ ID NO. 49;
- VII-7 The heavy chain variable region shown in SEQ ID NO.27 and the light chain variable region shown in SEQ ID NO.53;
- the heavy chain variable region and the light chain variable region comprise a heavy chain CDR and a light chain CDR selected from any one of the following combinations:
- H-CDR1 GYSITSDYAWN
- H-CDR2 YIDYSGSTTYNPSLKS
- H-CDR3 TVIDSMDY
- SEQ ID NO. 56, 63, 70 shown in SEQ ID NO. 56, 63, 70; and, shown in SEQ ID NO. 85, 93 , 97 L-CDR1 (RASKSVSTSGHSYMH), L-CDR2 (LASNLES), L-CDR3 (QHSREFPFT);
- H-CDR1 GYTFTDSEMY
- H-CDR2 AIDPETGDTAFNQKFKG
- H-CDR3 AFDNDNDDGFAY
- SEQ ID NO.59, 66, 73 shown in SEQ ID NO.89 , 95, 100 L-CDR1 (SASSSVNYMH), L-CDR2 (DTSKLAS), L-CDR3 (QQWSSNPLT);
- H-CDR1 GYTFTDSEMY
- H-CDR2 AIDPETGDTAFNQKFKG
- H-CDR3 AFDNDNDEGFAY
- SEQ ID NO.59, 66, 74 shown in SEQ ID NO.89 , 95, 100 L-CDR1 (SASSSVNYMH), L-CDR2 (DTSKLAS), L-CDR3 (QQWSSNPLT);
- H-CDR1 GYTFTDSEMY
- H-CDR2 AIDPETGDTAFNQKFKG
- H-CDR3 AFDNDNDDAFAY
- SEQ ID NO.59, 66, 75 shown in SEQ ID NO.89 , 95, 100 L-CDR1 (SASSSVNYMH), L-CDR2 (DTSKLAS), L-CDR3 (QQWSSNPLT);
- V-6 H-CDR1 (GYTFTDYELH), H-CDR2 (TIDPETGDTVYNQKFKA), H-CDR3 (AFYNDYDDAFAY) shown in SEQ ID NO. 60, 67, 78; and, shown in SEQ ID NO. 90 , 95, 102 L-CDR1 (SVSSSVSYMH), L-CDR2 (DTSKLAS), L-CDR3 (QQWNTSPLT);
- VI-3) H-CDR1 (GYRFTDSEMH), H-CDR2 (TIDPETGGTVYNQKFKG), H-CDR3 (AFYNDFDDAFAY) shown in SEQ ID NO. 61, 68, 81 in sequence; and, shown in SEQ ID NO. 91 , 95, 100 L-CDR1 (SASTSVSYMH), L-CDR2 (DTSKLAS), L-CDR3 (QQWSSNPLT);
- the light chain variable region comprises an amino acid sequence shown in any one of SEQ ID NO. 29 to SEQ ID NO. 53 or an amino acid sequence having at least 75% identity with the amino acid sequence.
- the antibody or fragment thereof of the present invention comprises a heavy chain variable region and a light chain variable region selected from any one of the following combinations:
- (I-1) The heavy chain variable region shown in SEQ ID NO. 1 and the light chain variable region shown in SEQ ID NO. 29;
- (I-2) The heavy chain variable region shown in SEQ ID NO. 2 and the light chain variable region shown in SEQ ID NO. 30;
- (II-1) The heavy chain variable region shown in SEQ ID NO. 4 and the light chain variable region shown in SEQ ID NO. 32;
- V-1) The heavy chain variable region shown in SEQ ID NO. 15 and the light chain variable region shown in SEQ ID NO. 42;
- V-2) the heavy chain variable region shown in SEQ ID NO.16 and the light chain variable region shown in SEQ ID NO.43;
- V-7 the heavy chain variable region shown in SEQ ID NO.17 and the light chain variable region shown in SEQ ID NO.45;
- V-8 the heavy chain variable region shown in SEQ ID NO.18 and the light chain variable region shown in SEQ ID NO.43;
- V-9 The heavy chain variable region shown in SEQ ID NO.18 and the light chain variable region shown in SEQ ID NO.44;
- V-11 The heavy chain variable region shown in SEQ ID NO.19 and the light chain variable region shown in SEQ ID NO.43;
- V-12 The heavy chain variable region shown in SEQ ID NO.19 and the light chain variable region shown in SEQ ID NO.44;
- V-13 The heavy chain variable region shown in SEQ ID NO.19 and the light chain variable region shown in SEQ ID NO.45;
- VI-1) The heavy chain variable region shown in SEQ ID NO.20 and the light chain variable region shown in SEQ ID NO.46;
- VI-2 The heavy chain variable region shown in SEQ ID NO.21 and the light chain variable region shown in SEQ ID NO.47;
- VI-4 The heavy chain variable region shown in SEQ ID NO. 22 and the light chain variable region shown in SEQ ID NO. 47;
- VI-7 The heavy chain variable region shown in SEQ ID NO.23 and the light chain variable region shown in SEQ ID NO.48;
- VI-8 The heavy chain variable region shown in SEQ ID NO. 24 and the light chain variable region shown in SEQ ID NO. 47;
- VI-9 The heavy chain variable region shown in SEQ ID NO. 24 and the light chain variable region shown in SEQ ID NO. 48;
- VII-2 The heavy chain variable region shown in SEQ ID NO. 26 and the light chain variable region shown in SEQ ID NO. 52;
- VII-3) The heavy chain variable region shown in SEQ ID NO.26 and the light chain variable region shown in SEQ ID NO.53;
- VII-4 The heavy chain variable region shown in SEQ ID NO.26 and the light chain variable region shown in SEQ ID NO.50;
- VII-5 The heavy chain variable region shown in SEQ ID NO.26 and the light chain variable region shown in SEQ ID NO.51;
- VII-6) The heavy chain variable region shown in SEQ ID NO. 27 and the light chain variable region shown in SEQ ID NO. 52;
- VII-9 The heavy chain variable region shown in SEQ ID NO.27 and the light chain variable region shown in SEQ ID NO.51;
- VII-10) The heavy chain variable region shown in SEQ ID NO. 28 and the light chain variable region shown in SEQ ID NO. 52;
- VI-11 The heavy chain variable region shown in SEQ ID NO. 28 and the light chain variable region shown in SEQ ID NO. 53;
- VII-12 The heavy chain variable region shown in SEQ ID NO. 28 and the light chain variable region shown in SEQ ID NO. 50;
- VI-13 The heavy chain variable region shown in SEQ ID NO.28 and the light chain variable region shown in SEQ ID NO.51.
- the antibody or fragment thereof provided by the present invention binds ST2, preferably mammalian ST2, more preferably primate ST2, further preferably human or cynomolgus ST2, especially human ST2.
- ST2 preferably mammalian ST2
- primate ST2 preferably human or cynomolgus ST2, especially human ST2.
- the fragment is a functionally active fragment of the antibody that can specifically bind to ST2 or any part thereof; more preferably, the fragment is scFv, BsFv, dsFv, (dsFv) 2 , Fab, Fab of the antibody ', F(ab') 2 or Fv fragment.
- the antibody or fragment thereof comprises a heavy chain constant region selected from IgG, IgA, IgM, IgD or IgE and/or a kappa or lambda light chain constant region.
- the antibody further comprises a heavy chain constant region, the heavy chain constant region is of the IgG1, IgG2 or IgG4 subtype; or, the antibody further comprises a light chain constant region, the light chain constant The region is of ⁇ type; further preferably, the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO. 54 or an amino acid sequence having at least 75% identity with the amino acid sequence; the light chain constant region comprises SEQ The amino acid sequence shown in ID NO. 55 or an amino acid sequence having at least 75% identity with the amino acid sequence.
- the present invention provides the following antibodies:
- variable region of the heavy chain is shown in SEQ ID NO.11
- variable region of the light chain is shown in SEQ ID NO.41;
- variable region of the heavy chain is shown in SEQ ID No. 16
- variable region of the light chain is shown in SEQ ID No. 44;
- the heavy chain constant regions of the above antibodies are shown in SEQ ID NO.54, and the light chain constant regions are shown in SEQ ID NO.55.
- the antibody is a monoclonal antibody, comprising two heavy chains and two light chains.
- the present invention also provides a conjugate or fusion protein comprising the antibody or fragment thereof of the present invention.
- the conjugate or fusion protein may include other parts that are bound to the antibody or fragments of the present invention by chemical or physical methods, such as cell surface receptors, small molecule compounds such as amino acids and carbohydrates, small molecule polymers, or other parts of the present invention. Any other part of the antibody that is modified, or even an active protein or polypeptide.
- the present invention also provides a nucleic acid molecule that encodes the heavy chain CDR, light chain CDR, heavy chain variable region, light chain variable region, heavy chain, or light chain in any antibody or fragment thereof of the present invention.
- the present invention provides a vector comprising the nucleic acid molecule of the present invention.
- the vector can be a eukaryotic expression vector, a prokaryotic expression vector, an artificial chromosome, a phage vector, and the like.
- the antibodies or fragments thereof and corresponding conjugates or fusion proteins, nucleic acid molecules, vectors and/or host cells provided by the present invention can be obtained by using any conventional technical methods known in the art.
- the antibody or fragments thereof, conjugates or fusion proteins, nucleic acid molecules, vectors and/or host cells can be included in the composition, more particularly in a pharmaceutical composition, such as a pharmaceutical preparation, so as to meet actual needs. Used for various purposes.
- the present invention also provides a composition comprising the antibody or fragments, conjugates or fusion proteins, nucleic acid molecules, vectors and/or host cells of the present invention.
- the composition is a pharmaceutical composition, which optionally further comprises pharmaceutically acceptable excipients.
- the present invention provides the use of the antibody or its fragments, conjugates or fusion proteins, nucleic acid molecules, vectors, host cells and/or compositions in the preparation of drugs for the prevention, treatment or amelioration of diseases; preferably
- the disease is related to ST2 expression or IL-33/ST2 pathway dysregulation; preferably, the disease is an inflammatory disease or an autoimmune disease; more preferably, the disease is heart failure, allergic rhinitis, rhinitis Polyps, atopic dermatitis, chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, sepsis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Wegener's granuloma or chemotherapy related Sexual diarrhea.
- the present invention provides a method for preventing, treating or ameliorating a disease, the method comprising administering the antibody or fragment, conjugate or fusion protein, nucleic acid molecule, or nucleic acid molecule of the present invention to a subject in need thereof
- the vector, host cell and/or composition, and optionally other drugs or means comprising administering the antibody or fragment, conjugate or fusion protein, nucleic acid molecule, or nucleic acid molecule of the present invention to a subject in need thereof.
- the optional other drugs or means refer to other hormone drugs or immunomodulatory drugs that can be administered in combination with the antibody or fragments, conjugates or fusion proteins, nucleic acid molecules, vectors, host cells and/or compositions of the present invention or Means, such as glucocorticoids, mepolizumab, dupilumab, Tezepelumab, etc.
- the combined administration of the two can be carried out in any form, for example, simultaneously, continuously or at a certain time interval.
- the subject is a mammal, preferably a primate, more preferably a human or cynomolgus monkey; preferably, the subject is a human.
- human ST2 is used to immunize mice, the culture supernatant is obtained by B cell panning, and positive clones are obtained through ELISA screening and further functional screening; further, mouse antibodies are humanized through antibody engineering. Humanized antibody.
- human ST2 is used to immunize mice, the culture supernatant is obtained by B cell panning, and positive clones are obtained through ELISA screening and further functional screening; further, mouse antibodies are humanized through antibody engineering. Humanized antibody.
- the affinity determination of antibodies and the in vivo drug metabolism of animals proved Compared with the existing anti-ST2 antibody, the antibody of the present invention has higher biological activity.
- Figures 1 to 5 show the inhibition rate of KU812 NF- ⁇ B reporter gene activity of B cell clones from mice with different numbers. Among them, Figure 1: 5883 mice; Figure 2: 5884 mice; Figure 3: 5886 mice; Figure 4: 5887 mice; Figure 5: 5888 mice.
- Figure 7 shows the binding of murine antibodies to cyno ST2.
- Figure 8 shows the binding of murine antibodies to mouse ST2.
- Figure 9 shows that the humanized antibody inhibits IL33 binding to human ST2 activity.
- Figure 11 shows that the humanized antibody inhibits the KU812-IL5 production activity of oxidized IL33.
- Figure 12 shows that the humanized antibody inhibits the KU812-IL5 production activity of reduced IL33.
- Figure 14 shows that the humanized antibody inhibits the IL33-promoting HMC-1IL8 production activity.
- Figure 15 shows the mouse PK curve of the humanized antibody, where 15-1: 5888-116-H0L1; 15-2: 5888-153-H0L1; 15-3: CNTO7160; 15-4: 5886-156- H1L0.
- Human ST2-his Human ST2 with 6 histidine tags fused to the C-terminus
- human ST2-fc Human ST2 with human IgG1Fc tag fused to the C-terminus
- Human IL33-his Human IL33 with 6 histidine tags fused to the C terminal
- Oxidized human IL33-his Dilute Human IL-33-his with IMDM to 300 ⁇ g/ml, incubate at 37°C for 18 hours, and then use S75 16:600 Superdex column (GE Healthcare) to purify
- Control antibody CNTO7160 heavy chain is shown in SEQ ID NO.104, light chain is shown in SEQ ID NO.105
- Cyno ST2-fc Cyno ST2 with human IgG1Fc tag fused to the C-terminus
- Mouse ST2-fc Mouse ST2 with human IgG1Fc tag fused to the C-terminus
- CHO-K1 cells were used to express Human ST2-his, and then 6 BALB/c mice were immunized according to the routine Freund's adjuvant immunization procedure. The immunization was carried out in two batches, with 3 mice in each batch, two weeks apart between the two batches. Each batch of mice was immunized 4 times, and the Human ST2-his was used for ELISA detection. If the titer of the mouse serum is greater than 1:100,000, the final immunization was performed, and the spleen was collected 3-4 days later.
- the collected spleens of the immunized mice were ground, filtered, and centrifuged, and red blood cells were removed with red blood cell lysate, and repeated until there were no obvious red blood cells; then DC cells in the spleen cells were removed.
- Splenocytes obtained from a spleen were evenly added to the above-mentioned 6-well plate coated with antigen for panning.
- B cells after antigen panning were collected and counted with trypsin, and then plated on the above-mentioned feeder cells. In a 96-well plate. Incubate at 37°C and 5% CO 2 for about 10-14 days, and take the B cell culture supernatant that has formed obvious clones in the well for the following screening.
- the test results showed that the negative control (blank medium) OD value of more than 10 times was used as the positive criterion.
- the B cell clones from the two mice numbered 5883 and 5884 were tested on the mouse anti-binding human ST2-his ELISA screening results. The positive rate is over 97%.
- Dilute human IL33-his with culture medium to 1 ⁇ g/mL mix it with B cell culture supernatant 1:1 as a test sample, and prepare a negative control sample (diluted human IL33-his is mixed with blank medium 1:1) and Positive control samples (diluted human IL33-his mixed with 1 ⁇ g/mL CNTO7160 1:1) were added to a 384-well plate at 20 ⁇ L/well.
- mouse antibody The name of the mouse antibody is expressed by the cell clone number from which the light and heavy chains (H+L) are contained.
- the mouse antibody "5883-105H+L” means the mouse antibody from the 5883-105 cell clone, and its heavy chain is 5883-105H , The light chain is 5883-105L.
- Human ST2-his was diluted to 1 ⁇ g/mL with coating buffer, 50 ⁇ L/well was added to a 96-well plate, and coated overnight at 4°C; the next day, the coated plate was taken out and washed with PBST for 3 times; then with blocking solution at room temperature Incubate for 1 h, and then wash 3 times with PBST.
- Use the diluent to dilute human IL33-his to 200ng/mL use the diluent to dilute the mouse-derived antibody to an initial concentration of 200 ⁇ g/mL, and then dilute it 3 times for a total of 8 concentrations.
- Mouse anti-IL33 activates KU812 NF- ⁇ B reporter gene activity screening
- the anti-human ST2 antibody was diluted to 10nM and captured on the surface of protein A chip (capture time 60s). After antibody capture, human ST2-his was injected in the form of a solution (diluted two-fold from 11.8 nM to 0.7375 nM, 5 concentrations in total). The association was monitored for 4 minutes, and the dissociation was monitored for 10 minutes. The sensor surface was regenerated by injecting a pH2.0 glycine solution. The data generated for kinetics and affinity determination were analyzed using BIAevaluation software. The kinetic data is analyzed using a simple 1:1 combination model. The results are shown in Table 5.
- the capture antibody was coated one day in advance (it is a working solution that is 120 times diluted 240 ⁇ g/mL stock solution (PBS) to 2 ⁇ g/mL), and coated overnight at 4°C, 50 ⁇ L/well.
- the blocking solution was blocked for 1 hour and washed three times. Dilute the 120ng/mL standard solution 400 times to 300pg/mL, and then dilute it 2 times for a total of 7 concentrations. Take each 50 ⁇ L of cell culture supernatant and the diluted standard solution, add them to the ELISA well plate, and incubate for 2h.
- Cyno ST2-fc was diluted to 1 ⁇ g/mL with coating buffer, added to a 96-well plate at 50 ⁇ L/well, and coated overnight at 4°C; the next day, the coated plate was taken out and washed with PBST for 3 times; then with blocking solution at room temperature Incubate for 1 h, and then wash 3 times with PBST.
- Antibody EC 50 (ng/mL) Relative activity (%) 5883-105H+L 29.45 45.67 5886-130H2+L2 19.30 69.69 5886-156H+L 20.26 66.39 5887-30H2+L2 2.31 582.76 5887-41H+L 61.51 21.87 5887-257H2+L1 17.33 77.61 5887-537H3+L1 17.14 78.47 5888-209H+L 15.23 88.31 5888-378H+L 11.91 112.93 5887-127H3+L2 15.78 85.23 5887-167H+L 54.87 44.51 5888-15H2+L2 20.95 116.56 5888-116H1+L1 38.36 63.66 5888-120H2+L1 47.71 51.18 5888-153H1+L2 30.26 80.70 5888-297H1+L1 28.17 86.
- Mouse ST2-fc was diluted to 1 ⁇ g/mL with coating buffer, added 50 ⁇ L/well into 96-well plate, and coated overnight at 4°C; the next day, the coated plate was taken out and washed with PBST for 3 times; then with blocking solution at room temperature Incubate for 1 h, and then wash 3 times with PBST.
- Mouse-derived antibody was diluted 3 times starting from 1000ng/mL, and a total of 8 concentrations were added to a 96-well plate at 50 ⁇ L/well; incubated for 1h at room temperature, washed three times with PBST, and added goat anti-mouse secondary antibody (1:10000) at 50 ⁇ L /Well into a 96-well plate; incubate for 1h at room temperature, wash three times with PBST, add TMB to a 96-well plate according to 50 ⁇ L/well, shade for 10min, stop with 2M sulfuric acid 100 ⁇ L/well; read the OD450 value on the microplate reader , The result is shown in Figure 8. It can be seen that the mouse antibody binds to Mouse ST2 weakly, which is consistent with the control antibody CNTO7160.
- the heavy and light chain variable region sequences of seven murine antibodies were compared with human germline sequences.
- the comparison was a blast search of the IMGT database. Remove redundant genes and those with unpaired cysteines from this set of human germline genes. In both the framework and the CDR regions, the remaining human germline genes that are the closest match are selected as the recipient human framework.
- FR-4 was selected based on the sequence similarity of IGHJ/IGJK germline genes. Table 9 to Table 15 are 5886-156H+L, 5887-41H+L, 5887-537H3+L1, 5888-116H1+L1, 5888-153H1+L2, 5888-357H+L, 5888-379H1+L2, etc.
- the heavy chain constant region shown in SEQ ID NO.54 and the light chain constant region shown in SEQ ID NO.55 were used to construct a humanized light and heavy chain derived from the same mouse antibody, paired and transfected into CHO-K1 cells, and transfected After staining for 24 hours, add 10 ⁇ g/mL MSX for pressurization screening. After the cell density and viability are restored, inoculate for feed-batch expression. The centrifuged supernatant after expression is purified by protein A, and the antibody concentration is quantified by the BCA method for quantification filter.
- the collocation mode of the humanized antibody and its heavy and light chain variable regions is shown in Table 16 to Table 22.
- the suffix "ix" indicates that the antibody is a corresponding chimeric antibody.
- Humanized antibody inhibits IL33 from activating KU812 NF- ⁇ B reporter gene activity
- Antibody IC 50 (ng/mL) Relative activity Maximum inhibition rate 5886-156-H1L0 477.9 41.91% 92.49% 5887-41-H1L0 55.35 361.88% 89.24% 5888-116-H0L1 13.03 1537.22% 95.74% 5888-153-H0L1 43.78 457.51% 88.24% 5888-153-H1L1 12.36 1620.55% 91.36% 5888-153-H1L2 44.07 454.50% 84.98% 5888-153-H3L1 39.42 508.12% 86.11% 5888-153-H3L2 55.28 362.34% 88.11% CNTO7160 200.3 To 88.24%
- Antibody IC 50 ( ⁇ g/mL) Relative activity Maximum inhibition rate 5886-156-H1L0 0.7524 194.71% 93.38% 5887-41-H1L0 0.7056 207.62% 78.62% 5888-116-H0L1 0.1245 1176.71% 75.06% 5888-153-H0L1 0.3891 376.51% 83.56% 5888-153-H3L1 0.2646 553.67% 86.93% 5888-153-H3L2 0.5218 280.76% 87.24% 5888-379-H1L0 2.8650 51.13% 96.68% 5888-379-H2L1 2.8650 51.13% 96.68% CNTO7160 1.4650 100.00% 97.30%
- HUVEC cells were incubated for 18-24h under the conditions of 10,000 cells/well, 100 ⁇ L, 37°C and 5% CO 2 for 18-24 hours. Dilute human IL33-his with culture medium to 10ng/mL, humanized antibody with culture medium to 400 ⁇ g/mL, 4-fold dilution, a total of 11 concentrations, mix the two 1:1 and add 100 ⁇ L/well to the above In a 96-well plate, incubate at 37°C and 5% CO 2 for 18-24 hours.
- Antibody IC50( ⁇ g/mL) Relative activity Maximum inhibition rate 5886-156-H1L0 4.051 67.29% 87.89% 5887-41-H1L0 1.308 208.41% 93.20% 5888-116-H0L1 0.8321 327.60% 92.61% 5888-153-H0L1 0.8435 323.18% 92.99% 5888-153-H3L1 1.636 166.63% 93.05% 5888-153-H3L2 3.688 73.92% 91.85% 5888-379-H1L0 16.1 16.93% 83.05% 5888-379-H2L1 26.14 10.43% 71.60% CNTO7160 2.726 100.00% 66.59%
- the capture antibody 120-fold diluted (PBS) working solution
- the blocking solution was blocked for 1 hour and washed three times.
- the standard solution was diluted 40 times to 2000pg/mL, and then diluted 2 times for a total of 7 concentrations. Take each 50 ⁇ L of cell culture supernatant and the diluted standard solution, add them to the ELISA well plate, and incubate for 2h. Wash three times, add 60-fold diluted working solution of detection antibody, 50 ⁇ L/well, and incubate for 2h.
- the anti-human ST2 antibody was diluted to 2 ⁇ g/mL and captured on the surface of the Protein A chip for 60s. After antibody capture, human ST2-his in the form of a solution (initial concentration 20nM, 2-fold dilution with 6 concentrations) was injected. The association was monitored for 180s, and the dissociation was monitored for 700s, and the sensor surface was regenerated by injecting a pH2.0 glycine solution. The kinetic data was analyzed using a 1:1 combination model.
- the difference is that the dissociation is carried out under the condition of pH5.5 HBS-EP (1 ⁇ ) buffer, and the dissociation is monitored for 600s.
- mice were randomly divided into 4 groups, 5 mice in each group, and the dosing information is shown in Table 31.
- mice were administered separately, and the time of administration was recorded.
- Each group of mice before administration (0hr) and after administration 4hr, 8hr, 24hr (1d), 72hr (3d), 120hr (5d), 168hr (7d), 240hr (10d), 288hr (12d), 336hr (14d) Collect blood separately, collect serum, and store at -60 ⁇ -80°C.
- mouse PK plasma concentration The detection method of mouse PK plasma concentration is as follows:
- Stop and read 2M sulfuric acid, 100 ⁇ L/well, tap the plate and mix well. Calculate the concentration of the sample to be tested by reading at 450nm and reference 650nm.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
Abstract
Description
抗体 | ka(1/Ms) | kd(1/s) | KD(M) |
5883-105H+L | 1.59E+07 | 3.79E-03 | 2.39E-10 |
5886-130H2+L2 | 2.62E+06 | 1.78E-03 | 6.79E-10 |
5886-156H+L | 2.37E+06 | 1.09E-03 | 4.61E-10 |
5887-30H2+L2 | 6.95E+06 | 1.10E-02 | 1.58E-09 |
5887-41H+L | 1.10E+06 | 6.13E-04 | 5.60E-10 |
5887-257H2+L1 | 1.09E+06 | 7.50E-04 | 6.89E-10 |
5887-537H3+L1 | 5.01E+06 | 8.40E-04 | 1.68E-10 |
5888-209H+L | 9.85E+06 | 2.73E-03 | 2.77E-10 |
5888-378H+L | 1.07E+07 | 1.42E-03 | 1.34E-10 |
5887-127H3+L2 | 4.23E+06 | 1.05E-03 | 2.47E-10 |
5887-167H+L | 1.24E+06 | 6.99E-04 | 5.63E-10 |
5888-15H2+L2 | 5.16E+06 | 1.09E-03 | 2.10E-10 |
5888-116H1+L1 | 9.87E+06 | 1.11E-03 | 1.13E-10 |
5888-120H2+L1 | 1.29E+07 | 1.13E-03 | 8.75E-11 |
5888-153H1+L2 | 9.17E+06 | 8.64E-04 | 9.43E-11 |
5888-297H1+L1 | 1.02E+07 | 1.71E-03 | 1.68E-10 |
5888-357H+L | 4.38E+06 | 7.00E-04 | 1.60E-10 |
5888-379H1+L2 | 9.57E+05 | 5.46E-04 | 5.71E-10 |
5888-380H1+L2 | 7.13E+06 | 1.03E-03 | 1.45E-10 |
CNTO7160 | 8.27E+05 | 5.39E-04 | 6.98E-10 |
抗体 | 相对活性(%) | 最大抑制率(%) |
5883-105H+L | 342.64 | 80.33 |
5886-130H2+L2 | 344.54 | 71.06 |
5886-156H+L | 303.78 | 84.16 |
5887-30H2+L2 | 490.35 | 41.40 |
5887-41H+L | 128.40 | 79.25 |
5887-257H2+L1 | 40.03 | 82.17 |
5887-537H3+L1 | 766.96 | 62.25 |
5888-209H+L | 254.91 | 74.38 |
5888-378H+L | 466.20 | 84.53 |
5887-127H3+L2 | 126.96 | 73.54 |
5887-167H+L | 26.14 | 66.68 |
5888-15H2+L2 | 80.56 | 80.22 |
5888-116H1+L1 | 238.00 | 81.40 |
5888-120H2+L1 | 21.72 | 82.02 |
5888-153H1+L2 | 115.09 | 86.00 |
5888-297H1+L1 | 246.30 | 80.38 |
5888-357H+L | 98.54 | 71.03 |
5888-379H1+L2 | 19.17 | 92.72 |
5888-380H1+L2 | 69.84 | 77.33 |
CNTO7160 | 89.00 |
抗体 | EC 50(ng/mL) | 相对活性(%) |
5883-105H+L | 29.45 | 45.67 |
5886-130H2+L2 | 19.30 | 69.69 |
5886-156H+L | 20.26 | 66.39 |
5887-30H2+L2 | 2.31 | 582.76 |
5887-41H+L | 61.51 | 21.87 |
5887-257H2+L1 | 17.33 | 77.61 |
5887-537H3+L1 | 17.14 | 78.47 |
5888-209H+L | 15.23 | 88.31 |
5888-378H+L | 11.91 | 112.93 |
5887-127H3+L2 | 15.78 | 85.23 |
5887-167H+L | 54.87 | 44.51 |
5888-15H2+L2 | 20.95 | 116.56 |
5888-116H1+L1 | 38.36 | 63.66 |
5888-120H2+L1 | 47.71 | 51.18 |
5888-153H1+L2 | 30.26 | 80.70 |
5888-297H1+L1 | 28.17 | 86.69 |
5888-357H+L | 19.25 | 126.86 |
5888-379H1+L2 | 60.18 | 40.58 |
5888-380H1+L2 | 30.59 | 79.83 |
抗体 | ka(1/Ms) | kd(1/s) | KD(M) |
CNTO7160 | 1.63E+06 | 2.21E-04 | 1.36E-10 |
5886-156H+L | 3.62E+06 | 7.47E-04 | 2.06E-10 |
5887-41H+L | 7.98E+06 | 7.21E-04 | 9.03E-11 |
5887-537H3+L1 | 6.33E+06 | 5.11E-04 | 8.07E-11 |
5888-116H1+L1 | 8.14E+06 | 3.82E-04 | 4.69E-11 |
5888-153H1+L2 | 9.68E+06 | 1.39E-03 | 1.43E-10 |
5888-357H+L | 6.41E+06 | 8.26E-04 | 1.29E-10 |
5888-379H1+L2 | 4.78E+06 | 1.52E-04 | 3.17E-11 |
抗体 | IC 50(ng/mL) | 相对活性 | 最大抑制率 |
5886-156-H1L0 | 477.9 | 41.91% | 92.49% |
5887-41-H1L0 | 55.35 | 361.88% | 89.24% |
5888-116-H0L1 | 13.03 | 1537.22% | 95.74% |
5888-153-H0L1 | 43.78 | 457.51% | 88.24% |
5888-153-H1L1 | 12.36 | 1620.55% | 91.36% |
5888-153-H1L2 | 44.07 | 454.50% | 84.98% |
5888-153-H3L1 | 39.42 | 508.12% | 86.11% |
5888-153-H3L2 | 55.28 | 362.34% | 88.11% |
CNTO7160 | 200.3 | 88.24% |
抗体 | IC 50(μg/mL) | 相对活性 | 最大抑制率 |
5886-156-H1L0 | 0.0285 | 77.49% | 101.11% |
5887-41-H1L0 | 0.0337 | 65.40% | 101.12% |
5888-116-H0L1 | 0.0036 | 614.14% | 101.56% |
5888-153-H0L1 | 0.0147 | 150.07% | 101.47% |
5888-153-H3L1 | 0.0136 | 161.97% | 101.38% |
5888-153-H3L2 | 0.0173 | 127.44% | 101.37% |
5888-379-H1L0 | 0.0161 | 137.27% | 101.34% |
5888-379-H2L1 | 0.0228 | 96.84% | 101.14% |
CNTO7160 | 0.0221 | 100.00% | 98.90% |
抗体 | IC 50(μg/mL) | 相对活性 | 最大抑制率 |
5886-156-H1L0 | 0.7524 | 194.71% | 93.38% |
5887-41-H1L0 | 0.7056 | 207.62% | 78.62% |
5888-116-H0L1 | 0.1245 | 1176.71% | 75.06% |
5888-153-H0L1 | 0.3891 | 376.51% | 83.56% |
5888-153-H3L1 | 0.2646 | 553.67% | 86.93% |
5888-153-H3L2 | 0.5218 | 280.76% | 87.24% |
5888-379-H1L0 | 2.8650 | 51.13% | 96.68% |
5888-379-H2L1 | 2.8650 | 51.13% | 96.68% |
CNTO7160 | 1.4650 | 100.00% | 97.30% |
抗体 | IC50(μg/mL) | 相对活性 | 最大抑制率 |
5886-156-H1L0 | 4.051 | 67.29% | 87.89% |
5887-41-H1L0 | 1.308 | 208.41% | 93.20% |
5888-116-H0L1 | 0.8321 | 327.60% | 92.61% |
5888-153-H0L1 | 0.8435 | 323.18% | 92.99% |
5888-153-H3L1 | 1.636 | 166.63% | 93.05% |
5888-153-H3L2 | 3.688 | 73.92% | 91.85% |
5888-379-H1L0 | 16.1 | 16.93% | 83.05% |
5888-379-H2L1 | 26.14 | 10.43% | 71.60% |
CNTO7160 | 2.726 | 100.00% | 66.59% |
抗体 | IC50(μg/mL) | 相对活性 | 最大抑制率 |
5886-156-H1L0 | 0.1771 | 56.86% | 81.01% |
5887-41-H1L0 | 0.1234 | 81.60% | 77.81% |
5888-116-H0L1 | 0.005512 | 1826.92% | 90.57% |
5888-153-H0L1 | 0.03592 | 280.35% | 87.17% |
5888-153-H3L1 | 0.04719 | 213.39% | 86.75% |
5888-153-H3L2 | 0.09443 | 106.64% | 83.30% |
5888-379-H1L0 | 0.334 | 30.15% | 85.60% |
5888-379-H2L1 | 0.2298 | 43.82% | 90.15% |
CNTO7160 | 0.1007 | 82.34% |
抗体 | 给药方式 | 给药体积 | |
A | 5888-116-H0L1 | 5mg/kg i.p. | 0.1mL/10g |
B | 5888-153-H0L1 | 5mg/kg i.p. | 0.1mL/10g |
C | CNTO7160 | 5mg/kg i.p. | 0.1mL/10g |
D | 5886-156-H1L0 | 5mg/kg i.p. | 0.1mL/10g |
参数 | 5888-116-H0L1 | 5888-153-H0L1 | CNTO7160 | 5886-156-H1L0 |
t 1/2(h) | 174.78 | 191.46 | 241.97 | 241.18 |
Cmax(kg*ng/ml/mg) | 10972.58 | 9380.59 | 15733.80 | 11319.84 |
AUC(h*ng/ml) | 11509209.16 | 11404571.90 | 17097590.16 | 12860587.84 |
CL(ml/h/kg) | 0.31 | 0.30 | 0.18 | 0.26 |
MRT(h) | 139.03 | 146.65 | 146.40 | 147.33 |
Claims (15)
- 一种抗体或其片段,所述抗体或其片段包含重链可变区(VH)和轻链可变区(VL),其中所述重链可变区和轻链可变区包含选自以下组合中任一个所示的重链CDR和轻链CDR:(I):依次示于SEQ ID NO.56、63、70的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.85、93、97的L-CDR1、L-CDR2、L-CDR3;(II-1):依次示于SEQ ID NO.57、64、71的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.86、93、98的L-CDR1、L-CDR2、L-CDR3;(II-2):依次示于SEQ ID NO.57、64、71的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.87、93、98的L-CDR1、L-CDR2、L-CDR3;(III):依次示于SEQ ID NO.58、65、72的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.88、94、99的L-CDR1、L-CDR2、L-CDR3;(IV-1):依次示于SEQ ID NO.59、66、73的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.89、95、100的L-CDR1、L-CDR2、L-CDR3;(IV-2):依次示于SEQ ID NO.59、66、74的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.89、95、100的L-CDR1、L-CDR2、L-CDR3;(IV-3):依次示于SEQ ID NO.59、66、75的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.89、95、100的L-CDR1、L-CDR2、L-CDR3;(V-1):依次示于SEQ ID NO.60、67、76的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.90、95、101的L-CDR1、L-CDR2、L-CDR3;(V-2):依次示于SEQ ID NO.60、67、76的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.90、95、102的L-CDR1、L-CDR2、L-CDR3;(V-3):依次示于SEQ ID NO.60、67、77的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.90、95、101的L-CDR1、L-CDR2、L-CDR3;(V-4):依次示于SEQ ID NO.60、67、77的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.90、95、102的L-CDR1、L-CDR2、L-CDR3;(V-5):依次示于SEQ ID NO.60、67、78的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.90、95、101的L-CDR1、L-CDR2、L-CDR3;(V-6):依次示于SEQ ID NO.60、67、78的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.90、95、102的L-CDR1、L-CDR2、L-CDR3;(VI-1):依次示于SEQ ID NO.61、68、79的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.91、95、100的L-CDR1、L-CDR2、L-CDR3;(VI-2):依次示于SEQ ID NO.61、68、80的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.91、95、100的L-CDR1、L-CDR2、L-CDR3;(VI-3):依次示于SEQ ID NO.61、68、81的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.91、95、100的L-CDR1、L-CDR2、L-CDR3;(VII-1):依次示于SEQ ID NO.62、69、82的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.92、96、103的L-CDR1、L-CDR2、L-CDR3;(VII-2):依次示于SEQ ID NO.62、69、83的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.92、96、103的L-CDR1、L-CDR2、L-CDR3;(VII-3):依次示于SEQ ID NO.62、69、84的H-CDR1、H-CDR2、H-CDR3;和,依次示于SEQ ID NO.92、96、103的L-CDR1、L-CDR2、L-CDR3。
- 根据权利要求1所述的抗体或其片段,其特征在于,所述重链可变区包含SEQ ID NO.1至SEQ ID NO.28中任一个所示的氨基酸序列或者与所述氨基酸序列具有至少75%同一性的氨基酸序列;和/或,所述轻链可变区包含SEQ ID NO.29至SEQ ID NO.53中任一个所示的氨基酸序列或者与所述氨基酸序列具有至少75%同一性的氨基酸序列。
- 根据权利要求1或2所述的抗体或其片段,其特征在于,所述抗体或其片段包含选自以下组合中任一个所述重链可变区和轻链可变区:(I-1):SEQ ID NO.1所示的重链可变区和SEQ ID NO.29所示的轻链可变区;(I-2):SEQ ID NO.2所示的重链可变区和SEQ ID NO.30所示的轻链可变区;(I-3):SEQ ID NO.2所示的重链可变区和SEQ ID NO.31所示的轻链可变区;(I-4):SEQ ID NO.3所示的重链可变区和SEQ ID NO.30所示的轻链可变区;(I-5):SEQ ID NO.3所示的重链可变区和SEQ ID NO.31所示的轻链可变区;(II-1):SEQ ID NO.4所示的重链可变区和SEQ ID NO.32所示的轻链可变区;(II-2):SEQ ID NO.5所示的重链可变区和SEQ ID NO.33所示的轻链可变区;(II-3):SEQ ID NO.5所示的重链可变区和SEQ ID NO.34所示的轻链可变区;(II-4):SEQ ID NO.5所示的重链可变区和SEQ ID NO.35所示的轻链可变区;(II-5):SEQ ID NO.6所示的重链可变区和SEQ ID NO.33所示的轻链可变区;(II-6):SEQ ID NO.6所示的重链可变区和SEQ ID NO.34所示的轻链可变区;(II-7):SEQ ID NO.6所示的重链可变区和SEQ ID NO.35所示的轻链可变区;(III-1):SEQ ID NO.7所示的重链可变区和SEQ ID NO.36所示的轻链可变区;(III-2):SEQ ID NO.8所示的重链可变区和SEQ ID NO.37所示的轻链可变区;(III-3):SEQ ID NO.8所示的重链可变区和SEQ ID NO.38所示的轻链可变区;(III-4):SEQ ID NO.9所示的重链可变区和SEQ ID NO.37所示的轻链可变区;(III-5):SEQ ID NO.9所示的重链可变区和SEQ ID NO.38所示的轻链可变区;(IV-1):SEQ ID NO.10所示的重链可变区和SEQ ID NO.39所示的轻链可变区;(IV-2):SEQ ID NO.11所示的重链可变区和SEQ ID NO.40所示的轻链可变区;(IV-3):SEQ ID NO.11所示的重链可变区和SEQ ID NO.41所示的轻链可变区;(IV-4):SEQ ID NO.12所示的重链可变区和SEQ ID NO.40所示的轻链可变区;(IV-5):SEQ ID NO.12所示的重链可变区和SEQ ID NO.41所示的轻链 可变区;(IV-6):SEQ ID NO.13所示的重链可变区和SEQ ID NO.40所示的轻链可变区;(IV-7):SEQ ID NO.13所示的重链可变区和SEQ ID NO.41所示的轻链可变区;(IV-8):SEQ ID NO.14所示的重链可变区和SEQ ID NO.40所示的轻链可变区;(IV-9):SEQ ID NO.14所示的重链可变区和SEQ ID NO.41所示的轻链可变区;(V-1):SEQ ID NO.15所示的重链可变区和SEQ ID NO.42所示的轻链可变区;(V-2):SEQ ID NO.16所示的重链可变区和SEQ ID NO.43所示的轻链可变区;(V-3):SEQ ID NO.16所示的重链可变区和SEQ ID NO.44所示的轻链可变区;(V-4):SEQ ID NO.16所示的重链可变区和SEQ ID NO.45所示的轻链可变区;(V-5):SEQ ID NO.17所示的重链可变区和SEQ ID NO.43所示的轻链可变区;(V-6):SEQ ID NO.17所示的重链可变区和SEQ ID NO.44所示的轻链可变区;(V-7):SEQ ID NO.17所示的重链可变区和SEQ ID NO.45所示的轻链可变区;(V-8):SEQ ID NO.18所示的重链可变区和SEQ ID NO.43所示的轻链可变区;(V-9):SEQ ID NO.18所示的重链可变区和SEQ ID NO.44所示的轻链可变区;(V-10):SEQ ID NO.18所示的重链可变区和SEQ ID NO.45所示的轻链可变区;(V-11):SEQ ID NO.19所示的重链可变区和SEQ ID NO.43所示的轻链可变区;(V-12):SEQ ID NO.19所示的重链可变区和SEQ ID NO.44所示的轻链可变区;(V-13):SEQ ID NO.19所示的重链可变区和SEQ ID NO.45所示的轻链可变区;(VI-1):SEQ ID NO.20所示的重链可变区和SEQ ID NO.46所示的轻链可变区;(VI-2):SEQ ID NO.21所示的重链可变区和SEQ ID NO.47所示的轻链可变区;(VI-3):SEQ ID NO.21所示的重链可变区和SEQ ID NO.48所示的轻链可变区;(VI-4):SEQ ID NO.22所示的重链可变区和SEQ ID NO.47所示的轻链可变区;(VI-5):SEQ ID NO.22所示的重链可变区和SEQ ID NO.48所示的轻链可变区;(VI-6):SEQ ID NO.23所示的重链可变区和SEQ ID NO.47所示的轻链可变区;(VI-7):SEQ ID NO.23所示的重链可变区和SEQ ID NO.48所示的轻链可变区;(VI-8):SEQ ID NO.24所示的重链可变区和SEQ ID NO.47所示的轻链可变区;(VI-9):SEQ ID NO.24所示的重链可变区和SEQ ID NO.48所示的轻链可变区;(VII-1):SEQ ID NO.25所示的重链可变区和SEQ ID NO.49所示的轻链可变区;(VII-2):SEQ ID NO.26所示的重链可变区和SEQ ID NO.52所示的轻链可变区;(VII-3):SEQ ID NO.26所示的重链可变区和SEQ ID NO.53所示的轻链可变区;(VII-4):SEQ ID NO.26所示的重链可变区和SEQ ID NO.50所示的轻链可变区;(VII-5):SEQ ID NO.26所示的重链可变区和SEQ ID NO.51所示的轻 链可变区;(VII-6):SEQ ID NO.27所示的重链可变区和SEQ ID NO.52所示的轻链可变区;(VII-7):SEQ ID NO.27所示的重链可变区和SEQ ID NO.53所示的轻链可变区;(VII-8):SEQ ID NO.27所示的重链可变区和SEQ ID NO.50所示的轻链可变区;(VII-9):SEQ ID NO.27所示的重链可变区和SEQ ID NO.51所示的轻链可变区;(VII-10):SEQ ID NO.28所示的重链可变区和SEQ ID NO.52所示的轻链可变区;(VII-11):SEQ ID NO.28所示的重链可变区和SEQ ID NO.53所示的轻链可变区;(VII-12):SEQ ID NO.28所示的重链可变区和SEQ ID NO.50所示的轻链可变区;(VII-13):SEQ ID NO.28所示的重链可变区和SEQ ID NO.51所示的轻链可变区。
- 根据权利要求1至3中任一项所述的抗体或其片段,其特征在于,所述抗体或其片段结合ST2,优选哺乳动物ST2,更优选灵长类动物ST2,进一步优选人或食蟹猴ST2,特别是人ST2。
- 根据权利要求1至4中任一项所述的抗体或其片段,其特征在于,所述抗体为单克隆抗体、单链抗体、双功能抗体、单域抗体、纳米抗体、完全或部分人源化的抗体或者嵌合抗体等任意形式;优选地,所述抗体为IgA、IgD、IgE、IgG或IgM,更优选为IgG1、IgG2或IgG4;优选地,所述片段为所述抗体能够特异性结合ST2或其任何部分的功能活性片段;更优选地,所述片段为所述抗体的scFv、BsFv、dsFv、(dsFv) 2、Fab、Fab'、F(ab') 2或Fv片段;更优选地,所述抗体还包含重链恒定区,所述重链恒定区为IgG1、IgG2或IgG4亚型;或者,所述抗体还包含轻链恒定区,所述轻链恒定区为κ型;进一步优选地,所述重链恒定区包含SEQ ID NO.54所示的氨基酸序列或者与所述氨基酸序列具有至少75%同一性的氨基酸序列;所述轻链恒定区包含 SEQ ID NO.55所示氨基酸序列或者与所述氨基酸序列具有至少75%同一性的氨基酸序列;优选地,所述至少75%同一性为例如至少80%、优选至少85%、更优选至少90%、进一步优选至少91%、92%、93%、94%、95%、96%、97%、98%或甚至99%同一性等≥75%的任何百分比的同一性。
- 一种缀合物或融合蛋白,所述缀合物或融合蛋白包含权利要求1至5中任一项所述的抗体或其片段。
- 一种核酸分子,其编码权利要求1至6中任一项所述的抗体或其片段中的重链CDR、轻链CDR、重链可变区、轻链可变区、重链或轻链。
- 一种载体,其包含权利要求7所述的核酸分子。
- 一种宿主细胞,所述宿主细胞包含权利要求7所述的核酸分子和/或权利要求8所述的载体,或者所述宿主细胞被权利要求7所述的核酸分子和/或权利要求8所述的载体转化或转染。
- 一种组合物,所述组合物包含权利要求1至5中任一项所述的抗体或其片段、权利要求6所述的缀合物或融合蛋白、权利要求7所述的核酸分子、权利要求8所述的载体和/或权利要求9所述的宿主细胞;优选地,所述组合物为药物组合物,其任选地还包含药学上可接受的辅料。
- 权利要求1至5中任一项所述的抗体或其片段、权利要求6所述的缀合物或融合蛋白、权利要求7所述的核酸分子、权利要求8所述的载体、权利要求9所述的宿主细胞和/或权利要求10所述的组合物在制备用于预防、治疗或改善疾病的药物中的用途;优选地,所述疾病与ST2表达或IL-33/ST2途径失调相关;优选地,所述疾病为炎性疾病或自身免疫性疾病;更优选地,所述疾病为心力衰竭、过敏性鼻炎、鼻息肉、特应性皮炎、慢性阻塞性肺病、哮喘、肺纤维化、败血症、炎性肠病、系统性红斑狼疮、类风湿性关节炎、全身性硬化症、韦格纳氏肉芽肿或化疗相关性腹泻。
- 一种用于预防、治疗或改善疾病的方法,所述方法包括给有此需要的受试者施用权利要求1至5中任一项所述的抗体或其片段、权利要求6所述的缀合物或融合蛋白、权利要求7所述的核酸分子、权利要求8所述的载体、权利要求9所述的宿主细胞和/或权利要求10所述的组合物,以及任选 的其他药物或手段;优选地,所述疾病与ST2表达或IL-33/ST2途径失调相关;优选地,所述疾病为炎性疾病或自身免疫性疾病;更优选地,所述疾病为心力衰竭、过敏性鼻炎、鼻息肉、特应性皮炎、慢性阻塞性肺病、哮喘、肺纤维化、败血症、炎性肠病、系统性红斑狼疮、类风湿性关节炎、全身性硬化症、韦格纳氏肉芽肿或化疗相关性腹泻。
- 一种药物组合,其包含权利要求1至5中任一项所述的抗体或其片段、权利要求6所述的缀合物或融合蛋白、权利要求7所述的核酸分子、权利要求8所述的载体、权利要求9所述的宿主细胞和/或权利要求10所述的组合物,和任选的其他药物。
- 一种检测或诊断疾病的方法,所述方法包括使权利要求1至5中任一项所述的抗体或其片段、权利要求6所述的缀合物或融合蛋白、权利要求7所述的核酸分子、权利要求8所述的载体、权利要求9所述的宿主细胞和/或权利要求10所述的组合物与来自受试者的样品相接触;优选地,所述疾病与ST2表达或IL-33/ST2途径失调相关;优选地,所述疾病为炎性疾病或自身免疫性疾病;更优选地,所述疾病为心力衰竭、过敏性鼻炎、鼻息肉、特应性皮炎、慢性阻塞性肺病、哮喘、肺纤维化、败血症、炎性肠病、系统性红斑狼疮、类风湿性关节炎、全身性硬化症、韦格纳氏肉芽肿或化疗相关性腹泻。
- 一种试剂盒,所述试剂盒包括权利要求1至5中任一项所述的抗体或其片段、权利要求6所述的缀合物或融合蛋白、权利要求7所述的核酸分子、权利要求8所述的载体、权利要求9所述的宿主细胞和/或权利要求10所述的组合物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227029007A KR20220131970A (ko) | 2020-01-21 | 2021-01-21 | 항-st2 항체 및 그의 적용 |
EP21745196.2A EP4095160A4 (en) | 2020-01-21 | 2021-01-21 | ANTI-ST2 ANTIBODIES AND ITS APPLICATION |
AU2021210061A AU2021210061A1 (en) | 2020-01-21 | 2021-01-21 | Anti-ST2 antibody and application thereof |
CA3165698A CA3165698A1 (en) | 2020-01-21 | 2021-01-21 | Anti-st2 antibody and application thereof |
CN202180010756.2A CN115210260A (zh) | 2020-01-21 | 2021-01-21 | 抗st2抗体及其应用 |
JP2022544124A JP2023510972A (ja) | 2020-01-21 | 2021-01-21 | 抗st2抗体及びその適用 |
US17/794,582 US20230220086A1 (en) | 2020-01-21 | 2021-01-21 | Anti-st2 antibody and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010072085.X | 2020-01-21 | ||
CN202010072085.XA CN113214395A (zh) | 2020-01-21 | 2020-01-21 | 抗st2抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021147937A1 true WO2021147937A1 (zh) | 2021-07-29 |
Family
ID=76993069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/073009 WO2021147937A1 (zh) | 2020-01-21 | 2021-01-21 | 抗st2抗体及其应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230220086A1 (zh) |
EP (1) | EP4095160A4 (zh) |
JP (1) | JP2023510972A (zh) |
KR (1) | KR20220131970A (zh) |
CN (2) | CN113214395A (zh) |
AU (1) | AU2021210061A1 (zh) |
CA (1) | CA3165698A1 (zh) |
WO (1) | WO2021147937A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115703837A (zh) * | 2021-08-17 | 2023-02-17 | 东莞市朋志生物科技有限公司 | 一种抗生长刺激表达基因2蛋白的重组抗体 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116284388A (zh) * | 2021-07-21 | 2023-06-23 | 迈威(上海)生物科技股份有限公司 | 抗肿瘤抑制素2的抗体以及包含其的液体组合物 |
WO2023001258A1 (zh) * | 2021-07-21 | 2023-01-26 | 迈威(上海)生物科技股份有限公司 | 抗肿瘤抑制素2抗体的制药用途 |
CN117250356B (zh) * | 2023-05-23 | 2024-02-20 | 安徽千诚生物技术有限公司 | 一种定量检测可溶性st2蛋白的胶乳增强免疫比浊试剂盒及其制备方法 |
CN117024595B (zh) * | 2023-10-08 | 2024-01-26 | 江西乐成欣生生物技术研究有限责任公司 | 抗人st2的单克隆抗体及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030124624A1 (en) * | 2000-03-21 | 2003-07-03 | Medical Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for immunoassay of soluble human ST2 |
WO2013173761A2 (en) * | 2012-05-18 | 2013-11-21 | Amgen Inc. | St2 antigen binding proteins |
CN110357963A (zh) * | 2019-07-31 | 2019-10-22 | 北京智仁美博生物科技有限公司 | 抗人st2抗体及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2597288C2 (ru) * | 2011-02-23 | 2016-09-10 | Ф. Хоффманн-Ля Рош Аг | Антитела против человеческого il33r и их применение |
US8603470B1 (en) * | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
CN110045131B (zh) * | 2019-06-14 | 2019-09-03 | 迈威(上海)生物科技有限公司 | 用于测定人il-33/st2通路抑制剂的生物学活性的方法 |
-
2020
- 2020-01-21 CN CN202010072085.XA patent/CN113214395A/zh active Pending
-
2021
- 2021-01-21 EP EP21745196.2A patent/EP4095160A4/en active Pending
- 2021-01-21 JP JP2022544124A patent/JP2023510972A/ja active Pending
- 2021-01-21 CA CA3165698A patent/CA3165698A1/en active Pending
- 2021-01-21 WO PCT/CN2021/073009 patent/WO2021147937A1/zh unknown
- 2021-01-21 CN CN202180010756.2A patent/CN115210260A/zh active Pending
- 2021-01-21 US US17/794,582 patent/US20230220086A1/en active Pending
- 2021-01-21 KR KR1020227029007A patent/KR20220131970A/ko unknown
- 2021-01-21 AU AU2021210061A patent/AU2021210061A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030124624A1 (en) * | 2000-03-21 | 2003-07-03 | Medical Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for immunoassay of soluble human ST2 |
WO2013173761A2 (en) * | 2012-05-18 | 2013-11-21 | Amgen Inc. | St2 antigen binding proteins |
CN110357963A (zh) * | 2019-07-31 | 2019-10-22 | 北京智仁美博生物科技有限公司 | 抗人st2抗体及其用途 |
Non-Patent Citations (3)
Title |
---|
LINGEL ET AL., CELL, vol. 17, 2009, pages 1398 - 1410 |
See also references of EP4095160A4 |
WANG ET AL., NAT IMMUNOL, vol. 11, 2010, pages 905 - 11 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115703837A (zh) * | 2021-08-17 | 2023-02-17 | 东莞市朋志生物科技有限公司 | 一种抗生长刺激表达基因2蛋白的重组抗体 |
CN115703837B (zh) * | 2021-08-17 | 2023-10-03 | 东莞市朋志生物科技有限公司 | 一种抗生长刺激表达基因2蛋白的重组抗体 |
Also Published As
Publication number | Publication date |
---|---|
JP2023510972A (ja) | 2023-03-15 |
EP4095160A1 (en) | 2022-11-30 |
CA3165698A1 (en) | 2021-07-29 |
US20230220086A1 (en) | 2023-07-13 |
KR20220131970A (ko) | 2022-09-29 |
EP4095160A4 (en) | 2024-05-22 |
CN115210260A (zh) | 2022-10-18 |
CN113214395A (zh) | 2021-08-06 |
AU2021210061A1 (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021147937A1 (zh) | 抗st2抗体及其应用 | |
JP7437325B2 (ja) | Il-11ra抗体 | |
JP5502752B2 (ja) | 抗mif抗体 | |
EP3514180B1 (en) | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly | |
CN113056481A (zh) | Il-11抗体 | |
TWI635097B (zh) | 新穎抗人類tslp受體抗體 | |
TW201127401A (en) | Compositions and methods for treating inflammatory disorders | |
JP2023537422A (ja) | Il-11の抗体及びその使用 | |
WO2017198148A1 (zh) | 一种il-13抗体及其制备方法和应用 | |
WO2019096219A1 (zh) | 一种人源化抗il-13抗体及其制备方法和应用 | |
WO2023001258A1 (zh) | 抗肿瘤抑制素2抗体的制药用途 | |
JP6592600B2 (ja) | 抗cgrp/抗il−23二重特異性抗体及びその使用 | |
JP2022513331A (ja) | ヒト化抗N短縮型アミロイドβモノクローナル抗体 | |
WO2023141815A1 (zh) | 抗生长分化因子15的抗体分子及其应用 | |
CN114395042B (zh) | 抗il-33人源化抗体及其应用 | |
WO2023051656A1 (zh) | 双特异性抗体及其应用 | |
WO2024027715A1 (en) | Anti-glp-1r antibodies and uses thereof | |
WO2022007965A1 (zh) | 一种抗IgE的工程化抗体及其应用 | |
TW202212359A (zh) | 結合人il-33的抗體、其製備方法和用途 | |
CN117586390A (zh) | 抗cgrp抗体及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21745196 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022544124 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3165698 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20227029007 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021210061 Country of ref document: AU Date of ref document: 20210121 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021745196 Country of ref document: EP Effective date: 20220822 |